The Journal of Experimental Medicine
Track the topics, authors and articles important to you
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents
Published online October 8, 2007
doi:10.1084/jem.20070458
The Journal of Experimental Medicine, Vol. 204, No. 11, 2641-2653
The Rockefeller University Press, 0022-1007 $30.00
© 2007 Shimizu et al.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow PPT slides of all figures
Right arrow Supplemental Material Index
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimizu, K.
Right arrow Articles by Fujii, S.-i.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimizu, K.
Right arrow Articles by Fujii, S.-i.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

ARTICLE

 Cross-presentation of glycolipid from tumor cells loaded with {alpha}-galactosylceramide leads to potent and long-lived T cell–mediated immunity via dendritic cells

Kanako Shimizu1, Yuri Kurosawa1, Masaru Taniguchi2, Ralph M. Steinman3, and Shin-ichiro Fujii1

1 Research Unit for Cellular Immunotherapy and 2 Laboratory for Immune regulation, Research Center for Allergy and Immunology, Institute of Physical and Chemical Research, Tsurumi-ku, Yokohama City, Kanagawa, 230-0045, Japan
3 Laboratory of Cellular Physiology and Immunology and Christopher H. Browne Center for Immunology and Immune Diseases, The Rockefeller University, New York, NY 10065

CORRESPONDENCE Shin-ichiro Fujii: fujiis{at}rcai.riken.jp

We report a mechanism to induce combined and long-lived CD4+ and CD8+ T cell immunity to several mouse tumors. Surprisingly, the initial source of antigen is a single low dose of tumor cells loaded with {alpha}-galactosylceramide ({alpha}-GalCer) glycolipid (tumor/Gal) but lacking co-stimulatory molecules. After tumor/Gal injection intravenously (i.v.), innate NKT and NK cells reject the tumor cells, some of which are taken up by dendritic cells (DCs). The DCs in turn cross-present glycolipid on CD1d molecules to NKT cells and undergo maturation. For B16 melanoma cells loaded with {alpha}-GalCer (B16/Gal), interferon {gamma}–producing CD8+ T cells develop toward several melanoma peptides, again after a single low i.v. dose of B16/Gal. In all four poorly immunogenic tumors tested, a single dose of tumor/Gal i.v. allows mice to become resistant to tumors given subcutaneously. Resistance requires CD4+ and CD8+ cells, as well as DCs, and persists for 6–12 mo. Therefore, several immunogenic features of DCs are engaged by the CD1d-mediated cross-presentation of glycolipid-loaded tumor cells, leading to particularly strong and long-lived adaptive immunity.

Abbreviations used: {alpha}-GalCer, {alpha}-galactosylceramide; B16/Gal, B16 melanoma cells loaded with {alpha}-GalCer; DC/Gal, DCs loaded with {alpha}-GalCer; DCT, dopachrome tautomerase; DTR, diphtheria toxin receptor; MNC, mononuclear cell; TAP, transporter associated with antigen presentation; TRP-2, tyrosinase-related protein 2; tumor/Gal, tumor cells loaded with {alpha}-GalCer.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS